Read
- IRS official refuses to answer questions at scandal hearing
- Bernanke comments spur volatility, but stocks, dollar gain
|
- British opposition leader says Google tax behavior 'wrong'
- Senate panel passes immigration bill; Obama praises move
- Rescuers search Oklahoma tornado town ruins as recovery starts
|
Reuters Photojournalism
Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography. See more | Photo caption
Sponsored Links
Pfizer kidney cancer drug gets EU approval
People walk past the Pfizer World headquarters in New York, February 3, 2010.
Credit: Reuters/Brendan McDermid
(Reuters) - Pfizer Inc said its oral drug Inlyta received European approval as a second-line treatment for kidney cancer patients who do not respond to an initial chemotherapy.
The company said the approval was based on data from a late-stage trial which showed that the drug significantly extended progression-free survival in patients who failed to respond to treatment with Pfizer's Sutent.
Inlyta was approved in the United States for the same indication in January.
The drug, generically known as axitinib, works by inhibiting proteins that can influence tumor growth and cancer progression.
Renal cell carcinoma affects 102,000 people in Europe every year, the company said in a statement.
Pfizer's shares closed at $23.86 on the New York Stock Exchange on Friday.
(Reporting By Vrinda Manocha in Bangalore; Editing by Anthony Kurian)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Follow Reuters